" class="no-js "lang="en-US"> Nutcracker Therapeutics Appoints Cynthia Collins to Board
Thursday, June 20, 2024

Nutcracker Therapeutics Appoints Cynthia Collins, Biopharma Veteran and Former Editas Medicine CEO, to Board of Directors

Nutcracker Therapeutics, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Cynthia Collins to the company’s board of directors.

Collins joins Nutcracker Therapeutics with more than four decades of experience working in the pharmaceutical and biotech industry. She currently is the lead director at Panavance Therapeutics Inc., a clinical stage pharmaceutical oncology company. Prior to her role at Panavance, she was the CEO of Editas Medicine from 2019 to 2021, where the first clinical trial administration of an in vivo CRISPR gene editing therapy took place under her leadership. Additionally, she is a board member of Poseida Therapeutics (PSTX), Certara (CERT), DermTech (DMTK), Draper Laboratories and Triumvira Immunologics.

“We are delighted to welcome Cindy to the board,” says Igor Khandros, Ph.D., CEO of Nutcracker Therapeutics. “Her career-spanning leadership and business experience in oncology, cell and gene therapies, and cutting-edge modalities, such as CRISPR, will be an instrumental asset to the team as we prepare for our first clinical trial with our lead candidate, NTX-250.”

Collins graduated from the University of Illinois Urbana-Champaign with a Bachelor of Science in Microbiology, and later went on to obtain her MBA at the University of Chicago Booth School of Business. Her previous executive roles in biopharma include CEO of Human Longevity; CEO/general manager of various life science businesses at GE Healthcare; president and CEO of GenVec; group vice president at Beckman Coulter; CEO and president of Sequoia Pharmaceuticals; and president of Global Oncology at Baxter Healthcare.

Cynthia joins Dr Khandros, Robert Nelsen of ARCH Venture Partners, Michael Bigham of Paratek Pharmaceuticals, and Dr Thomas Dietz of Waypoint Holdings (recently appointed) on Nutcracker Therapeutics’ board of directors.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more